

SYNTHESIS, CHARACTERIZATION AND ANTIMALARIAL STUDIES OF
SOME MONOCARBONYL CURCUMIN ANALOGS AND THEIR ARYL
HYDRAZONE DERIVATIVES

OLATOM DE AYODEJI FADARE

B.Sc., M.Sc. (Chemistry) (Ife)

SCP11/12/R0152

A THESIS SUBMITTED IN FULFILMENT OF THE REQUIREMENT FOR THE AWARD
OF THE DEGREE OF DOCTOR OF PHILOSOPHY IN THE DEPARTMENT OF
CHEMISTRY, FACULTY OF SCIENCE, OBAFEMI AWOLOWO UNIVERSITY

ILE-IFE, NIGERIA

2016

OBAFEMI AWOLOWO UNIVERSITY, ILE-IFE**HEZEKIAH OLUWASANMI LIBRARY****POSTGRADUATE THESIS****AUTHORISATION TO COPY****AUTHOR:** Olatomide Ayodeji **FADARE****TITLE:** Synthesis, Characterization and Antimalaria Studies of some
Mono Carbonyl Curcumin Analogs and their Aryl Hydrazone
Derivatives**DEGREE:** Ph. D (Organic Chemistry)**YEAR:** 2016

I, Olatomide Ayodeji **FADARE**, hereby authorize Hezekiah Oluwasanmi Library to copy my thesis in whole or in part, in response to requests from individual researchers and organizations for the purpose of private study or research.

Signature and Date:

.....

CERTIFICATION

We certify that this project work was carried out by **M. FADARE Olatunde Ayodeji** and Supervised by Prof. **C. A. Obafemi** (Chemistry Department, Obafemi Awolowo University, Ile-Ife) and Co-supervised by Prof. **E. O. Iwalawa** (Pharmacology Department, University of Ibadan, Ibadan) in partial fulfillment of the requirements for the award of Ph. D degree in Chemistry of the Obafemi Awolowo University, Ile-Ife, Ogun state, Nigeria.

| | | |
|----------------------------------|--------------------------|--------------------------------|
| | | |
| Supervisor | Co-supervisor | Head (Department of Chemistry) |
| Professor Gai g A Obafemi | Prof. E O Iwalawa | Prof. O O Soriyan |

ACKNOWLEDGEMENTS

With a deep sense of awe I express profound gratitude to the Almighty God for the grace and mercy that I received from him that allowed me to successfully complete this research work. I am saying a big thank you to my Supervisor, Prof C A Obafemi and my Co-supervisor, Prof E O Iwalewa for their professional and wise counsel as well as guidance during the course of this work. I also appreciate my colleagues and staff in the department of Chemistry and the Central Science Laboratory of Obafemi Awolowo University, Ile-Ife for all the support that I received during the course of this work. I acknowledge the organizations; Bodefence Emerging Infectious Diseases (BEI resources, USA), Malaria Research and Reference Reagent Resource Center (MR4, USA) who supplied the NK65 strain of the chloroquin sensitive strain of *Plasmodium berghei* used in this study as well as BioSolve IT, the provider of LeadIT tools package of which FlexX docking program is part of, for giving me a six weeks' license to use the HexX program for the molecular modelling aspect of this study.

I particularly would like to say a special thank you to the administration of, Obafemi Awolowo University, Ile-Ife, for the financial aid that I received during the course of this Ph. D program in the form of free tuition by virtue of being a member of staff of the university as well as my wife, Rachael and son, Tijesunimi for their moral support during the course of doing the laboratory research and the writing of the thesis.

TABLE OF CONTENTS

| | |
|-----------------------|-------|
| Authorisation to copy | ii |
| Certification | iii |
| Acknowledgments | iv |
| Table of contents | v |
| List of Appendices | x |
| List of Abbreviations | xiii |
| List of Figures | xv |
| List of Schemes | xxi |
| List of Tables | xxii |
| Abstract | xxiii |

CHAPTER ONE

| | | |
|--------|---|----|
| 1.0 | INTRODUCTION | 1 |
| 1.1 | Life Cycle of the Malaria Parasite and Progress of Disease in Man | 3 |
| 1.2 | Biochemistry of Parasite | 7 |
| 1.2.1. | Digestion of Hemoglobin | 7 |
| 1.2.2 | Detoxification of Free Heme | 14 |
| 1.2.3. | Degradation of Carbohydrates and Energy Production | 15 |
| 1.2.4. | Role of Folate in Nucleotide Synthesis | 17 |
| 1.2.5. | Redox Mechanism | 17 |

| | | |
|---------|--|----|
| 1.3 | Mechanism of Drug Action and Resistance | 18 |
| 1.3.1 | Inhibition of Hemoglobin Crystallization | 19 |
| 1.3.2 | Antifolates | 22 |
| 1.3.3 | Drugs that affect the Parasite's Redox Mechanism | 26 |
| 1.4 | Drugs Currently in use for Malaria Chemotherapy | 28 |
| 1.4.1 | Quinine Analogs | 31 |
| 1.4.2 | 4-Aminoquinoline Analogs | 32 |
| 1.4.3 | 8-Aminoquinolines | 33 |
| 1.4.4 | 9-Aminoacridines | 36 |
| 1.4.5 | Guaniidine Analogs (Biguanides) | 36 |
| 1.4.6 | Pyrimidine Analogs | 40 |
| 1.4.7 | Sulphones | 42 |
| 1.4.8 | Artemisinin | 45 |
| 1.4.9 | Mefloquine | 48 |
| 1.4.10 | Halofanthrine | 48 |
| 1.4.11 | Lumefantrine | 51 |
| 1.5 | Computer Aided Drug Design (CADD) | 51 |
| 1.5.1 | Ligand-Based Drug Design | 55 |
| 1.5.2 | Structure-Based Drug Design | 55 |
| 1.5.3 | Molecular Docking | 56 |
| 1.5.3.1 | Pose Functions | 63 |
| 1.5.3.2 | Scoring Functions | 65 |
| 1.5.4 | History of Medicinal Chemistry and Advances | |

| | |
|---|-----|
| in Molecular Modelling | 69 |
| CHAPTER TWO | |
| 2.0 LITERATURE REVIEW | 76 |
| 2.1 Curcumin | 76 |
| 2.2 Curcumin as an Antimalarial Agent | 79 |
| 2.3 Search for Super Curcumin | 82 |
| 2.4 Curcumin Derivatives | 87 |
| 2.5 Curcumin Analogs | 87 |
| 2.6 Metal Complexes | 88 |
| 2.7 Aims and Objectives | 96 |
| CHAPTER THREE | |
| 3.0 MATERIALS AND INSTRUMENTS | 97 |
| 3.1 General Details | 97 |
| 3.2 List of Reagents and Suppliers | 98 |
| 3.3 Software and X-Ray Crystallographic Data used for the Molecular Docking Study | 98 |
| 3.4 Experimental Animals for <i>In-Vivo</i> Assay | 99 |
| 3.5 Methodology | 99 |
| 3.5.1. Synthesis | 99 |
| 3.5.1.1 (1 <i>E</i> ,4 <i>E</i>)-1,5-diphenyl pent-1,4-dien-3-one, 1a | 99 |
| 3.5.1.2 (1 <i>E</i> ,4 <i>E</i>)-1,5-bis(4-hydroxy-3-methoxyphenyl) pent-1,4-dien-3-one, 2a | 100 |
| 3.5.1.3 (1 <i>E</i> ,4 <i>E</i>)-1,5-bis(4-methoxyphenyl) | |



| | | |
|---------|--|-----|
| | pent a-1,4-di en-3-one, 3a | 100 |
| 3.5.1.4 | (1 <i>E</i> 4 <i>E</i>)-1,5-bis(2-hydroxyphenyl) | |
| | pent a-1,4-di en-3-one, 4a | 100 |
| 3.5.1.5 | (1 <i>E</i> 4 <i>E</i>)-1-(naphthalene-1-yl)-5-(naphthalene-4-yl) | |
| | pent a-1,4-di en-3-one, 5a | 101 |
| 3.5.1.6 | (1 <i>E</i> 4 <i>E</i>)-1,5-bis(2-chloroquinolin-3-yl) | |
| | pent a-1,4-di en-3-one, 6a | 101 |
| 3.5.1.7 | (1 <i>E</i> 4 <i>E</i>)-1,5-bis(2-nitrophenyl) | |
| | pent a-1,4-di en-3-one, 7a | 102 |
| 3.5.2.1 | 2,4-di nitrophenyl hydrazone of compound 1a | 102 |
| 3.5.2.2 | 2,4-di nitrophenyl hydrazone of compound 2a | 103 |
| 3.5.2.3 | 2,4-di nitrophenyl hydrazone of compound 3a | 103 |
| 3.5.2.4 | 2,4-di nitrophenyl hydrazone of compound 4a | 104 |
| 3.5.2.5 | 2,4-di nitrophenyl hydrazone of compound 5a | 104 |
| 3.5.2.6 | 2,4-di nitrophenyl hydrazone of compound 6a | 105 |
| 3.5.2.7 | 2,4-di nitrophenyl hydrazone of compound 7a | 105 |
| 3.5.3 | 2,4-di nitrophenyl hydrazone of curcumin, 11e | 106 |
| 3.5.4 | Reaction Schemes | 107 |
| 3.6 | Molecular Modelling (Docking) Studies | 109 |
| 3.7 | Pharmacology | 109 |
| 3.7.1 | Acute Toxicity Test | 109 |
| 3.7.2 | <i>In-Vivo</i> Chemosuppressive Test | 110 |

CHAPTER FOUR

| | | |
|-------|---|-----|
| 4.0 | RESULTS AND DISCUSSION | 111 |
| 4.1 | Chemistry | 111 |
| 4.2 | Molecular Docking of Synthesized Compounds with Plasmodium II | 117 |
| 4.3 | Pharmacology | 133 |
| 4.4 | DISCUSSION | 142 |
| 4.4.1 | Infrared Spectroscopy | 142 |
| 4.4.2 | Ultraviolet-Visible Spectroscopy | 144 |
| 4.4.3 | Characterization of Pure Curcumin and its DNP Derivative. | 144 |
| 4.4.4 | Characterization of Compound 1a | 147 |
| 4.4.5 | Characterization of Compound 2a and derivative | 147 |
| 4.4.6 | Characterization of Compound 3a and its derivatives. | 149 |
| 4.4.7 | Molecular Modelling (Docking) | 152 |
| 4.5 | Pharmacology | 154 |
| 4.6 | Application of Lipid Based Drug Delivery System (LBDDS) in the Administration of Curcumin and Test Compounds | 163 |
| 4.7 | Survival Index | 170 |
| 4.8 | Short-Term Action and Parasite Recrudescence | 171 |
| 4.9 | Compounds with Good Chemoprevention and Survival Index Profiles | 171 |

CHAPTER FIVE

| | | |
|-----|------------|-----|
| 5.1 | CONCLUSION | 177 |
|-----|------------|-----|

| | | |
|-----|-----------------|-----|
| 5.2 | RECOMMENDATI ON | 178 |
| | References | 180 |
| | Appendi x | 204 |

OBAFEMI AWOLOWO UNIVERSITY

LIST OF APPENDICES

| Appendix | Caption | Page |
|-----------------|--|-------------|
| 1 | ¹ H NMR Spectrum for Compound 1a | 205 |
| 2a | ¹ H NMR Spectrum for Compound 7a | 206 |
| 2b | ¹ H NMR Spectrum for Compound 7a with Aromatic Region Expanded | 207 |
| 2c | ¹³ C NMR Spectrum for Compound 7a | 208 |
| 2d | ¹³ C NMR Spectrum (Attached Proton Test, APT) for Compound 7a | 209 |
| 3a | ¹ H NMR Spectrum for Compound 7b | 210 |
| 3b | ¹ H NMR Spectrum for Compound 7b | 211 |
| 3c | ¹³ C NMR Spectrum for Compound 7b | 212 |
| 3d | ¹³ C NMR (Attached Proton Test, APT) Spectrum for Compound 7b | 213 |
| 4a | ¹ H NMR Spectrum for Compound 3a | 214 |
| 4b | ¹ H NMR Spectrum for Compound 3a | 215 |
| 5 | ¹ H NMR Spectrum for Compound 3b | 216 |
| 6a | ¹ H NMR Spectrum for Compound 3c | 217 |
| 6b | ¹³ C NMR Spectrum for Compound 3c | 218 |
| 6c | ¹³ C NMR (Attached Proton Test, APT) Spectrum for Compound 3c | 219 |
| 6d | Heteronuclear Correlation NMR Experiment (HETCOR) for Compound 3c | 220 |
| 7 | ¹ H NMR Spectrum for Compound 2a | 221 |
| 8 | ¹ H NMR Spectrum for Compound 2b | 222 |



| | | |
|----|---|-----|
| 9 | ^1H NMR Spectrum for Compound 11d | 223 |
| 10 | ^1H NMR Spectrum for Compound 11e | 224 |
| 11 | Infrared Spectrum for Compound 1a | 225 |
| 12 | Infrared Spectrum for Compound 1b | 226 |
| 13 | Infrared Spectrum for Compound 2a | 227 |
| 14 | Infrared Spectrum for Compound 2b | 228 |
| 15 | Infrared Spectrum for Compound 3a | 229 |
| 16 | Infrared Spectrum for Compound 3b | 230 |
| 17 | Infrared Spectrum for Compound 3c | 231 |
| 18 | Infrared Spectrum for Compound 4a | 232 |
| 19 | Infrared Spectrum for Compound 4b | 233 |
| 20 | Infrared Spectrum for Compound 5a | 234 |
| 21 | Infrared Spectrum for Compound 5b | 235 |
| 22 | Infrared Spectrum for Compound 6a | 236 |
| 23 | Infrared Spectrum for Compound 6b | 237 |
| 24 | Infrared Spectrum for Compound 7a | 238 |
| 25 | Infrared Spectrum for Compound 7b | 239 |
| 26 | Infrared Spectrum for Compound 11d | 240 |
| 27 | Infrared Spectrum for Compound 11e | 241 |
| 28 | Ultraviolet-Visible Spectrum for Compound 1a | 242 |
| 29 | Ultraviolet-Visible Spectrum for Compound 1b | 243 |
| 30 | Ultraviolet-Visible Spectrum for Compound 2a | 244 |
| 31 | Ultraviolet-Visible Spectrum for Compound 2b | 245 |

| | | |
|-------|--|-----|
| 32 | Ultraviolet-Visible Spectrum for Compound 3a | 246 |
| 33 | Ultraviolet-Visible Spectrum for Compound 3b | 247 |
| 34 | Ultraviolet-Visible Spectrum for Compound 3c | 248 |
| 35 | Ultraviolet-Visible Spectrum for Compound 4a | 249 |
| 36 | Ultraviolet-Visible Spectrum for Compound 4b | 250 |
| 37 | Ultraviolet-Visible Spectrum for Compound 5a | 251 |
| 38 | Ultraviolet-Visible Spectrum for Compound 5b | 252 |
| 39 | Ultraviolet-Visible Spectrum for Compound 6a | 253 |
| 40 | Ultraviolet-Visible Spectrum for Compound 6b | 254 |
| 41 | Ultraviolet-Visible Spectrum for Compound 7a | 255 |
| 42 | Ultraviolet-Visible Spectrum for Compound 7b | 256 |
| 43 | Ultraviolet-Visible Spectrum for Compound 11d | 257 |
| 44 | Ultraviolet-Visible Spectrum for Compound 11e | 258 |
| 45-55 | 3D and 2D Poses from HexX for Compound 1a-8b | 259 |

LIST OF ABBREVIATIONS

ACT: Artemisinin combination therapies

ADME: Absorption, Distribution, Metabolism and Elimination

ATP: Adenosine triphosphate

BCS: Biopharmaceutical classification system

Caco-2 cells: Heterogeneous human epithelial colorectal adenocarcinoma cells

CDC: Centre for disease transmission and control

CQ: Chloroquine

CRT: Chloroquine resistant transporter

DDT: Dichlorodiphenyltrichloroethane

DHC: Dihydrocurcumin

DHFR: Dihydrofolate reductase

DHPS: Dihydropterotate synthase

DNA: Deoxyribonucleic acid

DNP: Dinutrophenyl hydrazine/ Dinutrophenyl hydrazone

DPAP: Dipeptidyl aminopeptidase

dTMP: Thymidine monophosphate

dUMP: Uridine monophosphate

FaSSIF: A patented complex of taurocholate and lecithin

GI T: Gastrointestinal tract

GTP: Guanosine-5'-triphosphate

Hb: Hemoglobin

HHC: Hexahydrocurcumin

Hz: Hemzoin

IgG Immunoglobulin G

IL-6 Interleukin 6

LBDDS: Lipid based drug delivery system

LDH Lactate dehydrogenase

LPS: lipopolysaccharide

MDR: Multi drug resistance

MDR1: Multi drug resistance transporter

NAD Nicotinamide adenine dinucleotide

NADH Reduced form of NAD

NADPH Nicotinamide adenine dinucleotide phosphate

OHC: Octahydrocurcumin

pABA: para- Aminobenzoic acid

PFOR: Pyruvate-ferredoxin oxidoreductase

PL: Phospholipid

ROI: Reactive oxygen intermediate

RT-PCR: Reverse transcription polymerase chain reaction

SI: Survival index

SMEDDS: Self-microemulsifying drug delivery system

SNEDDS: Self-nanoemulsifying drug delivery system

SOD Superoxide dismutase

TCA Tricarboxylic acid

TG Tri glyceri de

THC Tetrahydrocurcumin

TNF: Tumor necrosis factor

WHO: World health organization

LIST OF FIGURES

| Figure | Caption | Page |
|--------|--|------|
| 1.1 | Extent of Malaria Transmission in Different Regions of the World as at 2010. | 2 |
| 1.2 | Data on Reported Cases of <i>P. falciparum</i> Resistance to Clinical Antimalarial Drugs | 4 |
| 1.3 | Life Cycle of the Malaria Parasite. | 8 |
| 1.4 | (Heterotetramer, $(\alpha\beta)_2$) Structure of Human Hemoglobin | 11 |
| 1.5 | The Hemoglobin Digestion Pathway (Wser, 2008); | 13 |
| 1.6 | Pathway Showing the Degradation of Glucose by the Plasmodium to Yield Energy (ATP). | 16 |
| 1.7 | The Accumulation of Chloroquine (CQ) in the Food Vacuole of the Parasite. | 21 |
| 1.8 | Simplified Scheme of Folate Metabolism | 24 |
| 1.9 | Pathway Showing Actions of Nitroimidazoles. | 29 |
| 1.10 | The Quinine Alkaloids Extracted from the Bark of <i>Gnchona officinalis</i> | |

| | |
|--|----|
| Linn (<i>C ledgeriana</i> Moens) are Potent Anti malarial Agents | 31 |
| 1. 11 Tautomerism of Amodiaquine Base into the Iminoquinone Form | 34 |
| 1. 12 Hydroxychloroquine though an Anti malarial Drug is Also Effective in the Suppressive Treatment of Auto immune Inflammatory Diseases such as Rheumatoid Arthritis and Systemic Lupus Erythematosus. | 35 |
| 1. 13 8- Aminoquinoline Analogs Being Marketed as Anti malarial Drugs. | 37 |
| 1. 14 Mepacrine Mesylate and Mepacrine Hydrochloride Are Acridine Analogs | 38 |
| 1. 15 Aminoacridin along with its Structural Analogs Were Introduced as a Blend of 4- Aminoquinoline and 8- Aminoquinoline Features but they were not so Successful as a Result of their High Toxicity. | 39 |
| 1. 16 Structure of Proguanil and Mechanism of Cyclization to Form Cycloguanil the Active Metabolite. | 41 |
| 1. 17 Pyrimethamine and Trimethoprim which were Marketed with the Trade mark Names by Burroughs Wellcome. Trimethoprim was also Marketed with the Brand Name Trimex by Roche. | 43 |
| 1. 18 Sulfadoxine and Sulfamethopyrazine are Sulfanilamide Based Drugs. | 44 |
| 1. 19 Dapsone is 4,4-Diaminodiphenyl Sulfone and was Marketed as Avlosulfon® By Ayerst. | 46 |
| 1. 20 Artemisinin Derivatives Designed to be Soluble in Different Media, either Water Soluble or Lipid Soluble. | 47 |
| 1. 21 Mefloquine was Developed by the United States Military Research Department. | 49 |
| 1. 22 Halofanthrine, a Phenanthrene Methanol, is a Potent Inhibitor of the | |

| | | |
|------|--|----|
| | For mation of β -H ₂ mation by the Malaria Parasite. | 50 |
| 1.23 | Lumefantrine, a Fluorene Methanol, also a Potent Inhibitor of the For mation of β -H ₂ mation and is Used in Conjunction with Artemisinin Derivative, Especially Artemether, in ACTs. | 52 |
| 1.24 | A Drug Discovery Cycle Highlighting both Ligand-Based (Indirect) and Structure-Based (Direct) Drug Design Strategies. | 54 |
| 1.25 | 3D Representation of a Small Molecule Docked into a Binding Pocket of a Protein Molecule. | 57 |
| 1.26 | Some Docking Programs in a Pie Chart Showing the Extent to which they are Used Globally as at 2006. | 62 |
| 1.27 | Diagram Showing a Deviation of Only 20° in the Dihedral Φ of the Selective Estrogen Receptor Modulator Raloxifene which would Result in a Change of 2.5 Å in the Tertiary Amine Position, thereby Missing the Favorable Hydrogen-Bond Interaction with Asp351. | 64 |
| 1.28 | Scheme for Incremental Construction (<i>top line</i>) and Place-and-Join (<i>bottom line</i>) as Examples of the Mode of Operation of Systematic Search Algorithms. | 66 |
| 2.1 | (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl) hepta-1,6-diene-3,5-dione (diferyl methane) | 77 |
| 2.2 | Plant Derived Derivatives of Curcumin of which | |

| | |
|--|-----|
| Curcumin is the Most Studied | 83 |
| 2.3 Some other Plant Derived Compounds that have Structural Moieties that Resemble Curcumin | 84 |
| 2.4 Synthetic Derivatives of Curcumin – The Aryloxy (Phenolic) Group has been Modified in the Two Cases. | 85 |
| 2.5 Curcumin with Possible Positions for Structural Modification Highlighted. | 86 |
| 2.6 Synthetic Analogs of Curcumin | 89 |
| 2.7 Monocarbonyl Curcumin Analogs have the CH_2CO Group Removed. | 90 |
| 2.8 Monocarbonyl Curcumin Analogs Synthesized by Liang <i>et al.</i> , 2009b | 91 |
| 2.9 The Monocarbonyl Curcumins Can be Synthesized by the Claisen Schmidt Condensation of Substituted Aromatic Aldehydes (2 Mols Equivalent) with One Mole Equivalent of Either Acetone, Cyclohexanone or Cyclopentanone. | 92 |
| 2.10 Various Curcumin Derivatives – Review by . | |
| 2.11 A Synthesized Tetraoxane Ring System as Compared with the Trioxane Ring System in Artemisinin | 94 |
| 2.12 Novel Fluoro Knoevenagel Condensates and their Schiff Bases which were used to form Copper Complexes (Milacic <i>et al.</i> , 2008). | 95 |
| 4.1 Structure of Hasnepsin II Deduced from X-Ray Crystallographic Data. | 119 |
| 4.2 Chain A of Hasnepsin II with the Co-Crystallized Compound Embedded. | 120 |
| 4.3 Binding Site in Chain A of Hasnepsin II with the Co-Crystallized Compound Embedded. | 121 |
| 4.4 Binding Site in Chain A of Hasnepsin II with the Co-Crystallized | |

| | |
|---|-----|
| Compound Embedded. The Binding Site has Been Converted into a Surface. | 122 |
| 4.5 Binding Site in Chain A of Plasmodium without the Co-Crystallized Compound. | 123 |
| 4.6 (a) 3D Pose-View of Chloroquine Docked with Plasmodium | |
| (b) 2D Pose-View of Chloroquine Docked with Plasmodium. | 124 |
| 4.7 (a) 3D Pose-View of Compound 5a Docked with Plasmodium | |
| (b) 2D Pose-View of Compound 5a Docked with Plasmodium | 125 |
| 4.8 (a) 2D Pose-View of Compound 5b Docked with Plasmodium | |
| (b) 3D Pose-View of Compound 5b Docked with Plasmodium | 126 |
| 4.9 (a) 2D Pose-View of Compound 6a Docked with Plasmodium | |
| (b) 3D pose-view of compound 6a docked with plasmodium | 127 |
| 4.10 (a) 3D Pose-View of Compound 6b Docked with Plasmodium | |
| (b) 2D Pose-View of Compound 6b Docked with Plasmodium | 128 |
| 4.11 (a) 3D Pose-View of Compound 7a Docked with Plasmodium | |
| (b) 2D Pose-View of Compound 7a Docked with Plasmodium | 129 |
| 4.12 (a) 3D Pose-View of Compound 7b Docked with Plasmodium | |
| (b) 2D Pose-View of Compound 7b Docked with Plasmodium | |
| 4.13 (a) 3D Pose-View of Compound 10a Docked with Plasmodium | |
| (b) 2D Pose-View of Compound 10a Docked with Plasmodium | 131 |
| 4.14 (a) 3D Pose-View of Compound 10b Docked with Plasmodium | |
| (b) 2D Pose-View of Compound 10b Docked with Plasmodium | 132 |

- 4.15 Chart Showing % Chemosuppression and Survival Indices of Compound **1a** and **1b** at Three Different Doses (50, 100 and 200 mg/kg) in Comparison with Chloroquine at 10 mg/kg 135
- 4.16 Chart Showing % Chemosuppression and Survival Indices of Compound **2a** and **2b** at Three Different Doses (50, 100 and 200 mg/kg) in Comparison with Chloroquine at 10 mg/kg 136
- 4.17 Chart Showing % Chemosuppression and Survival Indices of compound **3a** and **3b** at Three Different Doses (50, 100 and 200 mg/kg) in Comparison with Chloroquine at 10 mg/kg 137
- 4.18 Chart Showing % Chemosuppression and Survival Indices of Compound **4a** and **4b** at Three Different Doses (50, 100 and 200 mg/kg) in Comparison with Chloroquine at 10 mg/kg 138
- 4.19 Chart Showing % Chemosuppression and Survival Indices of Compound **5a** and **5b** at Three Different Doses (50, 100 and 200 mg/kg) in Comparison with Chloroquine at 10 mg/kg 139
- 4.20 Chart Showing % Chemosuppression and Survival Indices of Compound **6a** and **6b** at Three Different Doses (50, 100 and 200 mg/kg) in Comparison with Chloroquine at 10 mg/kg 140
- 4.21 Chart Showing % Chemosuppression and Survival Indices of Compound **11d** and **11e** at Three Different Doses (50, 100 and 200 mg/kg) in Comparison with Chloroquine at 10 mg/kg 141
- 4.22 Keto-Enol Tautomerism Showing the Extension in Conjugation that the Extra CHCO Affords and the Hydrogen Bonding within

| | |
|--|-----|
| a Pseudo Six- Membered Ring System | 143 |
| 4.23 The Suggested Cyclized Product from the Reaction of Curcumin with 2,4-Dinitrophenyl Hydrazine. The Product is Thought to be a Pyrazole which is Typical for Reactions of Curcumin with Hydrazine Derivatives from Literature. | 146 |
| 4.24 (a) Comparison of Compound 2a with Curcumin. Compound 2a is the Monocarbonyl Curcumin Analog that Resembles Curcumin the most. | |
| (b) Analysis of the ¹ H NMR Spectrum of Compound 2b | 148 |
| 4.25 (a) Analysis of the ¹ H NMR Spectrum of Compound 2e Showing the Symmetry in the Aromatic Rings and the Entire Molecule. | |
| (b) Analysis of the ¹ H NMR Spectrum of compound 4e Showing the Loss of Symmetry in the Entire Molecule and the Splitting of the CH Protons in the Pyrazoline Moiety of the Molecule | 151 |
| 4.26 Schematic Diagram Showing the Route of the Drug After Oral Ingestion and Through the Gastrointestinal Tract, Depicting the Extent to Which the Drug is Absorbed (Goodman and Gilman, 2006). | 156 |
| 4.27 Pathway Showing the Degradation of Curcumin when Administered Orally and when Administered Intraperitoneal or Intravenous. | 159 |
| 4.28 The Portion (CH ₃ CO) of the Parent Curcumin that is Excluded in the Monocarbonyl Curcumin Analog | 161 |
| 4.29 The Biopharmaceutics Classification System (BCS) as Defined by the FDA | 166 |
| 4.30 Structures of Some of the Compounds Synthesized in this Work that Have a Good Chemoprevention and Survival Index Profile. | |

Some of These Drugs May Be Considered for Further Tests.

176

OBAFEMI AWOLOWO UNIVERSITY

LIST OF SCHEMES

| Scheme | Caption | Page |
|---------------|--|-------------|
| 3.1 | Scheme Showing the Reaction of Substituted Benzaldehydes with Acetone to form the Monocarbonyl Curcumin Analogs. | 107 |
| 3.2 | Scheme showing the Reaction of the Synthesized Monocarbonyl Curcumin with 2,4-dinitrophenyl Hydrazine (DNP) to form the Corresponding DNP Hydrazones (1-7h). Reaction of Compound 3a with 4-nitro Phenyl Hydrazine to form a Pyrazoline Derivative (3c) and Reaction of Pure Curcumin (11d) with DNP to form a DNP Pyrazolone Derivative (11e). | 108 |

LIST OF TABLES

| Table | Caption | Page |
|--------------|--|-------------|
| 1. 1 | Food vacuole proteases in <i>Plasmodium falciparum</i> | 10 |
| 1. 2 | Antifolate combinations used in malaria chemotherapy | 26 |
| 1. 3 | Possible redox agents | 28 |
| 1. 4 | Table of docking soft wares with country of origin and year of publication | 59 |
| 4. 1 | Table of physicochemical properties | 112 |
| 4. 2 | Nuclear magnetic resonance spectroscopic data of some of the synthesized compounds | 113 |
| 4. 3 | Nuclear magnetic resonance spectroscopic data for pure curcumin and the DNP pyrazole | 115 |
| 4. 4 | Prominent Infrared absorption bands from the spectra of the synthesized compounds | 116 |
| 4. 5 | Binding energy of synthesized compounds with plasmapsin II | 118 |

ABSTRACT

The study synthesized mono carbonyl analogs of curcumin, the aryl hydrazone derivatives of the mono carbonyl curcumin analogs and a 2,4-dinitrophenyl pyrazolone derivative of curcumin itself. The synthesized compounds were then characterized, docked with plasmapsin II, and the acute toxicity of the synthesized compounds as well as the percentage chemosuppression of the rodent strain of malaria parasite (*Plasmodium berghei*) NK65(CS) were determined. This was with a view to establishing the compounds suitable for a curative assay and discovering new potent and relatively non-toxic synthetic analogs of curcumin that could be used to combat *Plasmodium falciparum* which is the malaria causal organism in man.

The monocarbonyl curcumins were synthesized by a simple Claisen-Schmidt condensation reaction by reacting two molar equivalents of a substituted benzaldehyde with a molar equivalent of acetone in acidic/basic conditions to yield compounds **1a-7a**. The monocarbonyl curcumins were then reacted with a molar equivalent of 2,4-dinitrophenyl hydrazine with stirring in ethanol (at room temperature) under acid catalysis for 18 hrs to yield the corresponding DNP hydrazone **1b-7b**. Compound **3a** was reacted with 4-nitrophenylhydrazine under the same conditions as DNP which resulted into a pyrazoline, **3c**. Curcumin was also reacted with DNP under the same condition to yield a pyrazolone, **11e**. The synthesized compounds were then characterized using spectroscopic techniques such as UV-Visible, IR, ¹H and ¹³C NMR spectroscopy. The synthesized compounds were docked with plasmapsin II, one of the enzymes used by the parasite to digest haemoglobin, using flexX, a part of the LeadIT tools to estimate the binding affinity of the compounds for the protein as a function of antimalarial activity. All the synthesized compounds were tested *in-vivo* using a four day chemosuppressive assay for their antimalarial activity. The test animals were monitored afterwards for 24 days to assess the

longer effect of the drug on the test models and to estimate the survival index (SI) of the test models with respect to the test compounds. The compounds were administered using a lipid based drug delivery system (cotton seed oil was used as the vehicle for the compounds administered orally).

The binding energies computed for the compounds ranged from -19.29 to -35.96 kJ/mol. Chloroquine was used as a control molecule and all the compounds had binding affinity greater than that of chloroquine (-17.02 kJ/mol). Some of the compounds docked had high affinity for the plasmeprin II. Compounds **1b**, **4b**, **5b**, **6a**, **6b**, **7b** and **10b** had binding energies ranging from -25 to -36 kJ/mol. Among the compounds listed, only compound **6a** was a monocarbonyl curcumin analog of curcumin. Compounds **1a** (83.72 % chemosuppression at 200 mg/kg and SI of 68.75 %), **2b** (81.93% chemosuppression at 200 mg/kg and SI of 50 %), **3a** (58.62 % chemosuppression at 200 mg/kg and SI of 100 %), **5a** (66.59 % chemosuppression at 100 mg/kg and SI of 68.75 %), **6a** (71.2 % chemosuppression at 50 mg/kg and SI of 46.15 %) and **11e** (74.09 % chemosuppression at 50 mg/kg and SI of 54.55 %) were the compounds that had the best combination of survival index and chemosuppression profiles.

This study concluded that the compounds **1a**, **2b**, **3a**, **5a**, **6a** and **11e** had high chemosuppression compared to curcumin which was comparable to chloroquine and could therefore be selected for a curative *in-vivo* assay.

CHAPTER ONE

1.0 INTRODUCTION

Malaria is a deadly infectious disease caused by a blood-borne protozoan of the genus *Plasmodium* (*P*) and is transmitted by the female *Anopheles* mosquito. There are more than 120 species of the protozoan from the genus *Plasmodium* of which five are currently known to infect humans: *P. falciparum*, *P. vivax*, *P. malariae*, *P. knowlesi* and *P. ovale*. (Chin *et al.*, 1965; Jongwutiwes *et al.*, 2004; Cox-Singh *et al.*, 2008). Malaria is the second leading cause of death from infectious disease in Africa, where 89 % of worldwide malaria deaths occur (Figure 1.1) (About malaria – CDC, 2014). According to the World Health Organization's statistics on malaria, over 200 million people (including children) are infected yearly. In 2012 malaria caused 207 million clinical episodes, and 627, 000 people died from malaria and the number has increased steadily since then.

Malaria is characterized by periodic bouts of severe chills and high fever. Serious cases of malaria can result in death if left untreated. Among the five species of the plasmodium known to afflict humans, *P. falciparum* causes the most severe form of human malaria and results in a majority of the reported fatalities worldwide.

After repeated infections, people who live in regions where malaria is prevalent develop a limited immunity to the disease. This partial protection does not prevent them from developing malaria again, but does protect them against the most serious effects of the infection. They generally develop a mild form of the disease that does not last long and is unlikely to be fatal.

Infants and children are especially vulnerable to malaria because they have not yet built up immunity to the parasite. Some people have genetic traits that help them resist malaria. Sickle-

cell anemia and thalassemia, for example, are inherited blood disorders linked to malaria resistance. Over the years, the malaria parasite has developed resistance to existing drugs used




Figure 1.1: Extent of Malaria Transmission in Different Regions of the World as at 2010.

Source is Centre for Disease Transmission and Control, United States of America, www.cdc.gov (“Guidelines for the Treatment of Malaria” World Health Organization. <<http://helidigitalcollection.org/en/d/Js13418e/14.6.html>>).

to treat the disease. Recent data reveals documented cases of drug resistance by *Plasmodium falciparum*—the strain that causes the most severe clinical manifestation of the disease in man (Figure 1.2).

Artemisinin in combination with other anti-malarial drugs is the preferred mode of treatment nowadays due to low resistance of the parasite to artemisinin. Recently, however, cases of resistance to artemisinin have been reported in Cambodia and Thailand (Dondorp *et al.*, 2009). The development of resistance to existing drugs by the parasites makes it expedient that new anti-malaria drugs are developed for the treatment of the disease.

The disease vector (female anopheles mosquito) also constitute a problem in the eradication of the disease. Attempts to eradicate the disease in the absence of a vaccine has proved abortive over the years because of the continued existence of the disease vector in areas where the disease is endemic. When individuals are treated effectively with existing drugs, it cannot be guaranteed that they will not come down with the disease again since they are still exposed to the disease vector. The areas where the disease is endemic are areas where the vector thrives and is difficult to eradicate. The vector thrives in warm regions of the earth. The females which transmit the disease lay their eggs in water where their larvae develop and mature. Due to the prevalence of the mosquito in malaria endemic regions, basic anti-mosquito measures have been employed such as draining sites where mosquitoes lay their eggs, covering water channels, use of insecticide-

treated bed nets, spraying of insecticides and introducing into ponds fish that feed on mosquito larvae. The United States virtually eradicated malaria in the late 1940s and early 1950s through the use of the insecticide DDT. However, DDT was later banned in the United States and many other countries because of its harmful effects on the environment. Moreover, many species of *Anopheles* mosquitoes are now resistant to a wide range of insecticides, including DDT, as a result of the widespread use of these chemicals. Never

Malaria transmission areas and reported *P. falciparum* resistance, 2004




Figure 1.2: Data on Reported Cases of *P. falciparum* Resistance to Clinical Antimalarials

“Guidelines for the Treatment of Malaria” World Health Organization

(<http://helidigitalcollection.org/en/d/Js13418e/14.6.html>).

OBAFEMI AWOLOWO UNIVERSITY